Anastrozole Tablets
Anastrozole Tablets British Dragon — Overview
Anastrozole Tablets British Dragon contain anastrozole — a non-steroidal aromatase inhibitor (AI) that blocks the conversion of androgens into estrogen. Each tablet delivers 1 mg of anastrozole in a compact 100-tab pack, making it one of the most practical on-cycle estrogen management tools available at Steroid Warehouse.
This page covers how anastrozole works, which cycles require it, how it compares to other AIs in British Dragon's lineup, how to manage its own side effects, and why it should not be carried into post-cycle recovery.
About the Compound: Anastrozole
Anastrozole belongs to the triazole class of third-generation aromatase inhibitors. It works by competitively and reversibly binding to the aromatase enzyme (CYP19A1), blocking the conversion of androgens — primarily testosterone and androstenedione — into estradiol (E2). At a dose of 1 mg/day it suppresses circulating estrogen by approximately 70–85% in men. The inhibition is reversible, meaning estrogen levels return to baseline relatively quickly once dosing stops, which has practical implications for both cycle management and PCT timing.
The oral half-life of anastrozole is approximately 46–48 hours, which makes every-other-day (EOD) dosing a reliable protocol for maintaining stable E2 suppression without daily administration. Unlike exemestane, anastrozole carries no androgenic activity of its own — it is a purely functional estrogen-suppression tool.
What Anastrozole Does
Anastrozole does not produce anabolic or androgenic effects on its own. Its role in a cycle is strictly regulatory — it limits the estrogenic consequences of aromatizing androgens. In practice, athletes running testosterone-based or other aromatizing compounds report the following when anastrozole is correctly dosed:
- Reduced water retention and subcutaneous bloat — lower circulating E2 means less sodium and water retention, which translates into a leaner, drier appearance, particularly relevant during body composition phases.
- Gynecomastia prevention — by keeping E2 below the threshold where breast tissue stimulation occurs, anastrozole removes the main driver of gyno development in AAS cycles.
- Blood pressure management support — estrogenic compounds contribute to fluid-driven BP elevation; anastrozole reduces this load as part of a broader pressure management approach.
- Preserved training quality — when E2 is in range (not crashed), energy levels, joint comfort, and libido remain stable throughout the cycle, supporting consistent training output.
On dosing philosophy: Anastrozole is not a compound to run at maximum dose by default. The target is E2 in the 20–40 pg/mL range on cycle — low enough to prevent sides, high enough to preserve joint lubrication, mood stability, and cardiovascular markers. Bloodwork, not symptoms alone, should guide dose adjustments.
Who It Is For
Anastrozole is appropriate for any athlete running aromatizing androgens — primarily testosterone esters, Sustanon blends, or Dianabol-containing stacks. It is not needed on cycles built exclusively from non-aromatizing compounds such as Trenabol, Mastabol, Stanabol, or Oxanabol.
Anastrozole fits best in the following scenarios:
- First and second AAS cycles where testosterone is the base — anastrozole's predictable, reversible suppression makes it the more forgiving option for users learning how their body manages E2.
- Moderate aromatizing stacks (Testosterone Enanthate or Cypionate at 400–600 mg/week) where steady EOD dosing is sufficient and full aromatase blockade is not required.
- Longer cycles (12–20 weeks) where consistent, adjustable E2 management across many weeks is more practical than a stronger, less-titratable AI.
- Users who have previously over-suppressed E2 with letrozole — switching to anastrozole offers a lower ceiling and easier fine-tuning.
Users who should consider an alternative instead: those dealing with an active gynecomastia flare (Letrobol BD acts faster and more aggressively), and those planning to run anastrozole through PCT (switch to SERMs only — see PCT section below).
Anastrozole vs Alternatives
steroidwarehouse.com carries three aromatase inhibitors in the British Dragon lineup. The table below covers the key distinctions to help match the AI to the cycle.
| Compound | Key Differences | Choose This When | Choose Alternative When |
|---|---|---|---|
| Anastrozole Tablets BD (this product) |
Reversible competitive AI; 70–85% E2 suppression; well-established EOD protocol; easy to adjust dose mid-cycle. | Standard on-cycle E2 management; moderate aromatizing base (Test E/C 400–600 mg/wk); first experience with AIs; long cycles where titratability matters. | Active gyno flare requiring rapid suppression (use Letrobol); nearing PCT transition (switch to SERMs); steroidal AI preference for HDL preservation (use Exemestane). |
| Exemestane Tablets BD | Irreversible (suicidal) AI; steroidal structure with mild androgenic activity; tends to impact HDL less than non-steroidal AIs; no estrogen rebound after stopping. | End-of-cycle phase; users concerned about anastrozole's HDL impact; as a PCT bridge option before SERM-only recovery begins. | Ongoing management through a long cycle where reversibility is an advantage; users sensitive to androgenic activity from the AI itself. |
| Letrobol Tablets BD | Strongest of the three; up to ~98% E2 suppression possible; fastest onset for acute intervention; highest over-suppression risk. | Active gynecomastia flare-up; very high-aromatizing stacks (Test 750+ mg/wk + Dianabol + Decabol); salvage dosing when anastrozole proves insufficient. | Routine cycle management — too potent for standard use; joint pain and libido suppression are common at full dose; not suitable as a daily maintenance AI. |
Which Cycles Need Anastrozole
Anastrozole is a supporting tool, not a standalone compound. The table below matches common British Dragon aromatizing stacks to practical anastrozole dosing starting points — always adjust based on E2 bloodwork.
| Cycle / Stack | Aromatization Load | Starting Anastrozole Dose |
|---|---|---|
| Testabol Enanthate 400 mg/wk (solo) | Moderate | 0.25–0.5 mg EOD; check E2 at week 4 and adjust. |
| Sustabol 350 350–700 mg/wk | Moderate–High | 0.5 mg EOD; monitor closely — multi-ester blends aromatize across a wider release window. |
| Testabol Enanthate + Methanabol Tablets | High | 0.5–1 mg EOD; Dianabol adds significant estrogenic load — dose may need upward adjustment in weeks 1–4 while oral is running. |
| Testabol Propionate 300–500 mg/wk | Moderate | 0.25 mg EOD; shorter ester with more predictable peaks — lower starting dose often sufficient. |
| Testabol Enanthate + Decabol 250 | Moderate–High | 0.5 mg EOD throughout; nandrolone aromatizes at ~20% the rate of testosterone but adds to total estrogenic burden — maintain consistent anastrozole through the full cycle. |
Side Effects and How to Manage Them
Anastrozole's side effects differ from those of anabolic steroids — they arise from estrogen suppression rather than androgenic activity. The primary risk is dosing too aggressively and driving E2 below the functional range.
| What May Occur | Background | How to Handle It |
|---|---|---|
| E2 over-suppression (E2 crash) | The most common anastrozole problem. Estradiol below ~15 pg/mL causes joint pain, dry connective tissue, fatigue, low libido, and mood disruption — often mistaken for "cycle side effects" when the AI dose is actually too high. | Reduce dose or extend interval (EOD → E3D). Recheck E2 at 3–4 weeks. Do not simply push through — prolonged low E2 affects cardiovascular markers and bone metabolism. |
| HDL reduction | Non-steroidal AIs reduce HDL cholesterol by lowering estrogen, which plays a protective role in lipid metabolism. Effect is dose-dependent and additive with the lipid impact of the androgen base. | Monitor lipid panel every 6–8 weeks. Atorvastatin is the standard option when HDL drops significantly. Consistent cardio and omega-3 intake are recommended baseline habits on any cycle using an AI. |
| Joint discomfort | Even without a full E2 crash, low-normal estrogen reduces synovial fluid lubrication. Athletes often notice this in shoulders, knees, and elbows — particularly relevant in high-rep training or movements with significant joint stress. | Titrate anastrozole dose downward. If E2 is confirmed in range and joint discomfort persists, evaluate whether a non-aromatizing compound in the stack (Trenabol, Mastabol, Stanabol) is the primary driver. |
| Libido and mood effects | Estrogen contributes to CNS function, sexual motivation, and mood stability in men. Sustained over-suppression degrades all three — a telltale sign of an AI dose set too high relative to cycle aromatization. | Lower the AI dose and retest E2. If issues persist despite E2 in range, Taldabol (Tadalafil) addresses erectile function directly while E2 normalizes. |
| Blood pressure (from base AAS, not anastrozole itself) | Anastrozole reduces fluid-driven BP elevation from aromatization, but the androgen base may still raise BP through hematocrit, vasoconstriction, or other mechanisms independent of estrogen. | Ecosprin (Aspirin) 75 mg/day for cardiovascular support. If BP remains elevated, Amlodipine or Telmisartan are the commonly used options. |
Bloodwork Monitoring
Anastrozole is the compound being dosed to control the numbers below — bloodwork is the only reliable way to confirm it is working correctly and not over-suppressing.
| Lab | When to Test | Target & Action Threshold |
|---|---|---|
| Estradiol (E2) | Baseline pre-cycle; week 4 on cycle; every 4–6 weeks thereafter | 20–40 pg/mL on-cycle. Below 15 pg/mL: reduce AI dose or extend interval. Above 60 pg/mL: increase dose or frequency. |
| HDL / Lipid Panel | Baseline; at 6–8 weeks; end of cycle | HDL >40 mg/dL. If HDL falls >30% from baseline, consider adding Atorvastatin or reducing AI dose to allow partial E2 recovery. |
| Blood Pressure | Weekly throughout cycle | Target <130/85 mmHg. Anastrozole reduces estrogenic fluid load but does not fully control BP — monitor regardless of AI use. |
| Hematocrit / CBC | Baseline; at 6–8 weeks | Hematocrit <52%. Elevation is driven by the androgen base, not anastrozole — relevant for overall cycle health monitoring. |
| LH + FSH | At end of cycle / PCT start | Will be suppressed by AAS — confirms HPG axis shutdown and guides PCT aggressiveness. Anastrozole itself does not aid recovery and should be discontinued before PCT begins. |
| Total Testosterone (endogenous) | 4 weeks into PCT; PCT end | Rising trend toward normal range (300–800 ng/dL) confirms HPTA recovery. Persistently low levels at PCT end warrant extended recovery protocol. |
PCT — When to Stop Anastrozole
Anastrozole is discontinued at the end of the cycle — it is not used during post-cycle therapy. This is a critical point: running an AI into PCT actively suppresses the estrogen environment that the HPG axis needs to restart. Elevated E2 at the start of PCT is a signal the pituitary is responding; blocking it delays LH and FSH recovery.
Switch entirely to SERMs when PCT begins:
| Product | Role in PCT |
|---|---|
| Tamoxifen Tablets BD | Primary PCT SERM. Blocks estrogen receptors at the pituitary and hypothalamus, driving LH and FSH release to restart endogenous testosterone production without eliminating circulating E2. |
| Clomiphene Tablets BD | Run alongside Tamoxifen in the first half of PCT for stronger gonadotropin stimulation, especially after longer or heavier cycles where HPG suppression is deeper. |
For full PCT timing and dosing protocols, see the PCT guide.
Practical Summary
Key protocol rules for Anastrozole Tablets British Dragon:
- Use anastrozole only when the cycle includes aromatizing compounds (testosterone esters, Dianabol, Sustanon blends) — non-aromatizing stacks (Trenabol, Mastabol, Stanabol, Oxanabol) do not require it.
- Start at 0.25–0.5 mg EOD and adjust based on E2 bloodwork at week 4 — never increase dose solely based on water retention or mood, which can have non-estrogenic causes.
- Target on-cycle E2 of 20–40 pg/mL: below 15 means over-suppression; reduce dose immediately and retest in 3 weeks.
- Monitor HDL every 6–8 weeks; anastrozole's lipid impact is real and additive with that of the androgen base — have Atorvastatin on hand if HDL trends downward.
- Discontinue anastrozole when ending the cycle; do not carry it into PCT — switch entirely to Tamoxifen BD and Clomiphene BD for HPTA recovery.
- For gyno flare-up or very high-aromatizing stacks, upgrade to Letrobol Tablets BD — anastrozole is a maintenance AI, not a rescue compound.
Anastrozole remains one of the most consistently used aromatase inhibitors among athletes running testosterone-based cycles — valued precisely because its reversible mechanism allows dose adjustments mid-cycle without the commitment of a suicidal AI. Available at Steroid Warehouse in British Dragon's 1 mg/tab formulation, it fits established EOD protocols without splitting tablets or guessing sub-milligram doses. steroidwarehouse.com carries the complete British Dragon cycle support lineup — including Exemestane Tablets and Letrobol Tablets — so the right AI for every stage of a cycle is always within reach. Used at the lowest effective dose, guided by regular E2 testing, anastrozole keeps estrogenic sides controlled while preserving the hormonal balance that training progress and cycle recovery both depend on.
References
| Source | Topic | Link |
|---|---|---|
| New England Journal of Medicine / PubMed | Bhasin et al. 1996 — randomized controlled trial using 600 mg/week testosterone enanthate for 10 weeks in healthy men; showed increased fat-free mass, muscle size, and strength, with the largest gains when supraphysiologic testosterone was combined with resistance training | Bhasin S, et al. (1996) ↗ |
| NCBI Bookshelf / StatPearls | Anabolic steroids overview — clinical reference on synthetic testosterone-derived anabolic-androgenic steroids, androgen receptor activity, medical uses, misuse patterns, oral and injectable AAS forms, monitoring concerns, and adverse effect profile | StatPearls: Anabolic Steroids ↗ |
| NCBI Bookshelf / Endotext | Androgen physiology and pharmacology — detailed medical overview of testosterone, dihydrotestosterone, androgen receptor signaling, aromatization to estradiol, HPG-axis regulation, synthetic androgen use, and misuse-related endocrine suppression | Endotext: Androgen Physiology, Pharmacology, Use and Misuse ↗ |
| NCBI Bookshelf / StatPearls | Aromatase inhibitors — clinical pharmacology, mechanism of action, approved indications, estrogen suppression data, and adverse effect profile including lipid and bone effects | StatPearls: Aromatase Inhibitors ↗ |
| New England Journal of Medicine / PubMed | Finkelstein JS et al. 2013 — randomized trial isolating the contributions of testosterone and estradiol to body composition, strength, and sexual function in men; estrogen deficiency was the primary driver of increased body fat accumulation, while both testosterone and estradiol deficiency contributed to sexual function decline | Finkelstein JS, et al. (2013) ↗ |
What are Anastrozole Tablets?
Anastrozole Tablets are an oral aromatase inhibitor for estrogen control; see What Are Anastrozole Tablets. It prevents gynecomastia—consult professionals for safe use.
How long does Anastrozole stay in your system?
Detectable for ~10-14 days; see How Long Does Anastrozole Stay in Your System. Monitor with professional guidance.
What are Anastrozole Tablets used for in bodybuilding?
It's used to control estrogen and prevent gynecomastia; see What is Anastrozole Tablets Used For in Bodybuilding. It suits cycles—use with oversight.
How to take Anastrozole Tablets?
0.5-1 mg daily or EOD; see How to Take Anastrozole Tablets. Start low—consult professionals for dosing.
How long does it take to notice effects from Anastrozole Tablets?
Anastrozole begins reducing estrogen production relatively quickly, although noticeable effects depend on individual hormone levels and the specific purpose of use.
What are the main benefits of Anastrozole Tablets?
Commonly discussed benefits include estrogen management, support for hormonal balance, and reduction of estrogen-related effects associated with elevated estrogen levels.
What are the possible side effects of Anastrozole Tablets?
Potential side effects may include joint discomfort, headaches, fatigue, mood changes, and symptoms associated with excessively low estrogen levels.
What makes Anastrozole Tablets different from other estrogen-control products?
Anastrozole Tablets work by reducing estrogen production at its source through aromatase inhibition, making them distinct from compounds that primarily block estrogen receptors.
Related Products
